Lantern Pharma Inc. LTRN

Company Overview

Lantern Pharma Inc. is a U.S.-based clinical-stage biotechnology company focused on developing precision oncology therapies through the integration of artificial intelligence, machine learning, and genomic data analytics. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on cancer therapeutics targeting genetically defined patient populations. Lantern Pharma’s core strategy centers on identifying biomarker-driven cancer indications and optimizing drug development through its proprietary AI platform, RADR® (Response Algorithm for Drug Positioning & Rescue).

The company’s primary revenue-generating potential is tied to the advancement and commercialization of its oncology drug candidates, although it has historically generated limited operating revenue as a development-stage enterprise. Lantern Pharma’s pipeline includes compounds such as LP-300, LP-184, and LP-284, which are being evaluated for multiple cancer indications including lung cancer, glioblastoma, and hematologic malignancies. Originally founded in 2013 and later becoming publicly traded on the NASDAQ under the ticker LTRN, the company evolved from a drug repurposing and analytics-focused model into a precision oncology platform company emphasizing AI-enabled drug development efficiency and biomarker-guided therapies.